You are here:

emtricitabine/tenofovir disoproxil (Truvada)

Advice

following a full submission:

emtricitabine/tenofovir disoproxil (Truvada®) is accepted for use within NHS Scotland.

Indication under review: In combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.

In the pivotal studies conducted in men who have sex with men (iPrEx) and heterosexual couples, one of whom was HIV negative (Partners PrEP), there were statistically significant relative reductions in incidence of HIV for emtricitabine/tenofovir disoproxil compared with placebo. 

Drug Details

Drug Name: emtricitabine/tenofovir disoproxil (Truvada)
SMC Drug ID: 1225/17
Manufacturer: Gilead Sciences Ltd
Indication: In combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 10 April 2017

Back